Immuno-Oncology Panel Session

Kineticos recently tapped 3 industry veterans and Oncology experts to participate in a panel to discuss where we are today in terms of the Immuno-Oncology treatment landscape and what the future holds.  This third installment of the series discusses how biotechs can stand out amongst the myriad of drug developers seeking investment for their I/O programs.

Panel Members

  • Chris Heery – Chief Medical Officer, Bavarian Nordic
  • Jeff Kmetz – Former Chief Business Officer, Pulse Biosciences
  • Alex Dusek – Vice President of Commercial Strategy, Erytech

Click here for a condensed and edited version of Part 3.